Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

A definitive diagnosis of Chikungunya infection can be made only with the aid of laboratory support since clinically, symptoms resemble those of dengue fever. Laboratory diagnosis is therefore ...

Valneva (VALN) announced that it has submitted a label extension application to the U.S. Food and Drug Administration to potentially extend the use of its chikungunya vaccine IXCHIQ, which is ...